| Dr Michael T Dean, MD | |
|
2422 20th St Sw, Jamestown, ND 58401-6201 | |
| (701) 252-1050 | |
| (701) 952-3265 |
| Full Name | Dr Michael T Dean |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 38 Years |
| Location | 2422 20th St Sw, Jamestown, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427058676 | NPI | - | NPPES |
| 2726846 | Medicaid | MI | |
| 12034 | Other | ND | STATE LICENSE |
| P64646 | Other | MI | BLUE CARE NETWOK |
| 4213795 | Other | MI | AETNA |
| MD057401 | Other | MI | STATE LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | MD057401 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jamestown Regional Medical Center | Jamestown, ND | Hospital |
| Carrington Health Center | Carrington, ND | Hospital |
| St Aloisius Medical Center | Harvey, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lutheran Charity Association | 2264341031 | 30 |
News Archive
Baylor Scott & White Health today announces an alliance with Cleveland Clinic's Sydell and Arnold Miller Family Heart & Vascular Institute.
Electronics are showing up everywhere: on our laps, in pockets and purses and, increasingly, snuggled up against our skin or sewed into our clothing.
Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.
A multidisciplinary team of University of Utah Health scientists has received a five-year, $3 million grant from the National Institutes of variations in pollutant-sensing genes in the lungs could influence air pollution's effects on children who have asthma.
› Verified 1 days ago
| Entity Name | Lutheran Charity Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821044652 PECOS PAC ID: 2264341031 Enrollment ID: O20040128000565 |
News Archive
Baylor Scott & White Health today announces an alliance with Cleveland Clinic's Sydell and Arnold Miller Family Heart & Vascular Institute.
Electronics are showing up everywhere: on our laps, in pockets and purses and, increasingly, snuggled up against our skin or sewed into our clothing.
Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.
A multidisciplinary team of University of Utah Health scientists has received a five-year, $3 million grant from the National Institutes of variations in pollutant-sensing genes in the lungs could influence air pollution's effects on children who have asthma.
› Verified 1 days ago
| Entity Name | Lutheran Charity Association |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1548256753 PECOS PAC ID: 2264341031 Enrollment ID: O20080616000530 |
News Archive
Baylor Scott & White Health today announces an alliance with Cleveland Clinic's Sydell and Arnold Miller Family Heart & Vascular Institute.
Electronics are showing up everywhere: on our laps, in pockets and purses and, increasingly, snuggled up against our skin or sewed into our clothing.
Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.
A multidisciplinary team of University of Utah Health scientists has received a five-year, $3 million grant from the National Institutes of variations in pollutant-sensing genes in the lungs could influence air pollution's effects on children who have asthma.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael T Dean, MD 2422 20th St Sw, Jamestown, ND 58401-6201 Ph: (701) 252-1050 | Dr Michael T Dean, MD 2422 20th St Sw, Jamestown, ND 58401-6201 Ph: (701) 252-1050 |
News Archive
Baylor Scott & White Health today announces an alliance with Cleveland Clinic's Sydell and Arnold Miller Family Heart & Vascular Institute.
Electronics are showing up everywhere: on our laps, in pockets and purses and, increasingly, snuggled up against our skin or sewed into our clothing.
Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration has approved Mirvaso (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of rosacea in adults 18 years of age or older. Applied once daily, Mirvaso works quickly to reduce the redness of rosacea and lasts up to 12 hours. Galderma expects Mirvaso to be available in pharmacies September 2013.
A multidisciplinary team of University of Utah Health scientists has received a five-year, $3 million grant from the National Institutes of variations in pollutant-sensing genes in the lungs could influence air pollution's effects on children who have asthma.
› Verified 1 days ago